Genentech, a member of the Roche Group (RHHBY), said that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival or PFS and demonstrated that the combination of Tecentriq, or atezolizumab, plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone in the initial treatment of advanced non-squamous non-small cell lung cancer or NSCLC.
from RTT - Biotech https://ift.tt/2mqulcJ
via IFTTT
No comments:
Post a Comment